1. Bacteriophage lysins as antibacterials
- Author
-
Umender Sharma and Vivek Daniel Paul
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Letter ,medicine.drug_class ,Endolysin ,030106 microbiology ,Antibiotics ,MEDLINE ,Lysin ,Therapeutics ,Peptidoglycan ,Critical Care and Intensive Care Medicine ,Bacteriophage ,03 medical and health sciences ,Drug Resistance, Bacterial ,Humans ,Medicine ,Bacteriophages ,Phage Therapy ,Intensive care medicine ,biology ,business.industry ,Phage Particle ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,Quorum Sensing ,Antibacterial Peptide ,Bacterial Infections ,lcsh:RC86-88.9 ,biology.organism_classification ,030104 developmental biology ,Hemofiltration ,business - Abstract
The emergence of multi-drug resistant (MDR) microbial pathogens threatens the very foundation upon which standard antibacterial chemotherapy is based. We must consider non-antibiotic solutions to manage invasive bacterial infections. Transition from antibiotics to non-traditional treatments poses real clinical challenges that will not be easy to solve. Antibiotics will continue to reliably treat some infections (e.g., group A streptococci and Treponema pallidum) but will likely need adjuvant therapies or will need to be replaced for many bacterial infections in the future.
- Published
- 2017